… SHP2 abnormality and human disease makes SHP2 an attractive target for developing
mechanism-based therapy. Identification of highly bioactive and selective SHP2 inhibitors will be …

… of SHP2, and briefly review the development of SHP2 inhibitors. … tumor immunotherapy
using SHP2 inhibitors. We also discuss … inhibitor 2a as a selective SHP2 inhibitor (SHP2 IC 50 …

… a potential immunomodulator, controlling SHP2 activity is of significant … inhibitor of SHP2
was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2. …

… selective allosteric inhibitor of SHP2, RMC-4550 (1), to generate an in-depth understanding
of the integrated effects of SHP2 inhibition … unanticipated impact of SHP2 on tumor immunity …

… tunnel inhibitors, compound 1 was completely selective over … selectivity is a result of the
allosteric mechanism of inhibition which occurs via the ligands binding to the tunnel site of SHP2…

… Even though substantial advancements have been attained in the design of selective SHP2
inhibitors in the past two decades, a veritable breakthrough in the field happened only with …

… a highly potent (IC 50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2
… inhibition, we developed screening strategies aimed at identifying SHP2 allosteric inhibitors. …

… the SHP2 inhibitor SHP099 with a … inhibitors show limited efficacy as single agents, in
part because of the rapid development of adaptive resistance. We find that SHP2/MEK inhibitor …

… site of SHP2 with high selectivity and low toxicity are under development. This paper reviews
allosteric inhibitors of SHP2 … SHP2 has long been considered as an ‘undruggable’ protein. …

… Notably, various potent and selective SHP2 inhibitors have … SHP2 inhibitors and revisited
the SHP2-targeted anticancer strategies, and combination therapies with other PTK inhibitors …